Treatment of Diabetic Dyslipoproteinemia

 

 Buy Article Permissions and Reprints

Abstract

Diabetes mellitus, specifically type 2, is often associated with disorders in lipid metabolism. Elevated levels of plasma free fatty acids play a pivotal role by contributing significantly to insulin resistance. In addition free fatty acids promote diabetic dyslipidemia through increasing VLDL synthesis in the liver, and by virtue of cholesterylester transfer protein, modifying LDL to increase small-dense LDL subfractions and to decrease HDL cholesterol. This atherogenic lipoprotein profile (elevated triglycerides, increased small-dense low-density lipoproteins, and decreased high-density lipoproteins), contributes to the development of atherosclerosis and increases the risk of experiencing cardiovascular events, the most common cause of death in type 2 diabetes. To decrease the risk of cardiovascular disease events in diabetics, dyslipidemia needs to be treated, as evidenced from epidemiology, from intervention trials, and from subgroup analyses of large intervention trials initiated to evaluate effects of lipid lowering treatment that also included patients with type 2 diabetes.

Most measures used to counteract hyperglycemia, are also prone to ameliorate dyslipidemia: dietary intervention (medical nutrition) including ω-3 fatty acids as part of lifestyle changes that also comprise cessation of smoking, increases in physical activity and reduction in body weight. In addition insulin, biguanides, acarbose and glitazones applied for glycemic control also improve diabetic dyslipidemia.

Additional pharmacological treatment of dyslipidemia if persisting after glycemic control relies on different drug classes. Fibrates effectively reduce free fatty acids, fasting and postprandial lipemia, shift the distribution of LDL particles towards less dense subfractions and increase HDL cholesterol, thus particularly addressing key components of diabetic dyslipidemia. For LDL cholesterol lowering statins are mainly used that decrease LDL cholesterol levels by competitive inhibition of the HMG-CoA reductase. As type 2 diabetes is found to be associated with a two- to fourfold increase in coronary heart disease risk and as the degree of glycemia is more related to microvascular complications, correcting dyslipidemia appears to be a major task in order to reduce macrovascular events in patients with type 2 diabetes.

References

• 1 Albert C M, Campos H, Stampfer M J, Ridker P M, Manson J E, Willett W C, Ma J. Blood levels of long-chain n-3 fatty acids and the risk of sudden death.  N Engl J Med. 2002;  346 1113-1118
  CrossrefPubMedGoogle Scholar
• 2 American Diabetes Association . Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications.  Diabetes Care. 2002 a;  25 (Suppl 1) S50-S60
  PubMedGoogle Scholar
• 3 American Diabetes Association . Management of dyslipidemia in adults with diabetes.  Diabetes Care. 2002 b;  25 (Suppl 1) S74-S77
  PubMedGoogle Scholar
• 4 Austin M A, Breslow J L, Hennekens C H, Curing J E, Willett W C, Krauss R M. LDL subclass patterns and risk of myocardial infarction.  JAMA. 1988;  260 1917-1921
  CrossrefPubMedGoogle Scholar
• 5 Austin M A, Hokansen J E, Edwards K L. Hypertriglyceridemia as a cardiovascular risk factor.  Am J Cardiol. 1998;  81 7B-12B
  CrossrefPubMedGoogle Scholar
• 6 Austin M A. Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype.  Curr Atheroscl Reports. 2000;  2 200-207
  PubMedGoogle Scholar
• 7 Boden G. Effects of free fatty acids on glucose metabolism: Significance for insulin resistance and type 2 diabetes.  Exp Clin Endocrinol Diabetes. 2003;  111 121-124
  Article in Thieme ConnectPubMedGoogle Scholar
• 8 Boyle P J, King A B, Olansky L, Marchetti A, Lau H, Magar R, Martin J. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records.  Clin Therapeutics. 2002;  24 378-396
  PubMedGoogle Scholar
• 9 Brown B G, Hilger L, Zhao X Q, Poulin D, Albers J J. Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease.  Ann NY Acad Sci. 1995;  748 407-417
  PubMedGoogle Scholar
• 10 Brown B G, Zambon A, Poulin D, Rocha A, Mahler V MG, Davis J W, Albers J J, Brunzell J D. Use of niacin, statins, and resins in patients with combined hyperlipidemia.  Am J Cardiol. 1998;  81 52B-59B
  CrossrefPubMedGoogle Scholar
• 11 Canner P L, Berge K G, Wenger N K, Stamler J, Friedman L, Prineas R J, Friewald W. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin.  J Am Coll Cardiol. 1986;  8 1245-1255
  CrossrefPubMedGoogle Scholar
• 12 Coronary Drug Project Research Group . Clofibrate and niacin in coronary heart disease.  JAMA. 1975;  231 360-381
  CrossrefPubMedGoogle Scholar
• 13 Davies M J, Baer D J, Judd J T, Brown E D, Campbell W S, Taylor P R. Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women. A randomized controlled trial.  JAMA. 2002;  287 2559-2562
  CrossrefPubMedGoogle Scholar
• 14 Davignon J, Montigny M, Dufour R. HMG-CoA reductase inhibitors: a look back and a look ahead.  Can J Cardiol. 1992;  8 843-864
  PubMedGoogle Scholar
• 15 Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD) 2000 . Recommendations for the nutritional management of patients with diabetes mellitus.  Eur J Clin Nutr. 2000;  54 353-355
  CrossrefPubMedGoogle Scholar
• 16 Diabetes and Nutrition Study Group of the European Association for the Study of Diabetes . Recommendations for the nutritional management of patients with diabetes mellitus.  Diabetes Nutr Metab. 1995;  8 186-189
  PubMedGoogle Scholar
• 17 Diabetes Atherosclerosis Intervention Study Investigators . Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.  Lancet. 2001;  357 905-910
  CrossrefPubMedGoogle Scholar
• 18 Dunn C J, Peter D H. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.  Drugs. 1995;  49 721-749
  PubMedGoogle Scholar
• 19 Elam M B, Hunninghake D B, Davis K B, Garg R, Johnson C, Egan D, Kostis J B, Sheps D S, Brinton for the Investigators E AADMIT. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT Study: A randomized trial.  JAMA. 2000;  284 1263-1270
  CrossrefPubMedGoogle Scholar
• 20 Evans M, Khan N, Rees A. Diabetic dyslipidaemia and coronary heart-disease: new perspectives.  Curr Opin Lipidol. 1999;  10 387-391
  CrossrefPubMedGoogle Scholar
• 21 Executive Summary of the Third Report of the National Cholesterol Education Program expert panel on detection ( NCEP), evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel I II). .  JAMA. 2001;  285 2486-2497
  CrossrefPubMed
• 22 Farnier M, Picard S. . Diabetes; Statins, fibrates, or both? Curr Atheroscl Reports 2001 3: 19-28
• 23 Frost R JA, Otto C, Geiss H C, Schwandt P, Parhofer K G. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.  Am J Cardiol. 2001;  87 44-48
  PubMedGoogle Scholar
• 24 Fruchart J C, Brewer Jr H B, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group.  Am J Cardiol. 1998;  81 912-917
  CrossrefPubMedGoogle Scholar
• 25 Geiss H C, Dietlein M, Parhofer K G. Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia.  Exp Clin Endocrinol Diabetes. 2003;  (in press)
  PubMedGoogle Scholar
• 26 Gokcel A, Karakose H, Ertorer E M, Tanaci N, Tutuncu N B, Guvener N. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control.  Diabetes Care. 2001;  24 1957-1960
  PubMedGoogle Scholar
• 27 Goldberg R B, Mellies M J, Sacks F M, Moye L A, Howard W J, Davis B R, Cole T G, Pfeffer M A, Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol and recurrent events (CARE) trail. The Care Investigators.  Circulation. 1998;  98 2513-2519
  PubMedGoogle Scholar
• 28 Haffner S M, Alexander C M, Cook T J, Boccuzzi S J, Musliner T A, Pedersen T R, Kjekshus J, Pyörälä K. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.  Arch Intern Med. 1999;  159 2661-2667
  CrossrefPubMedGoogle Scholar
• 29 Haffner S M, Lehto S, Ronnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.  N Engl J Med. 1998;  339 229-234
  CrossrefPubMedGoogle Scholar
• 30 Haire-Joshu D, Glasgow R E, Tibbs T L. Smoking and diabetes.  Diabetes Care. 1999;  22 1887-1889
  PubMedGoogle Scholar
• 31 Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch H J, Lindner J, The Group D IS. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up.  Diabetologia. 1996;  39 1577-1583
  CrossrefPubMedGoogle Scholar
• 32 Heart Protection Study Collaborative Group . MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo controlled trail.  Lancet. 2002;  360 7-22
  CrossrefPubMedGoogle Scholar
• 33 Herrera E, Lasuncion M A, Castro M, Gomez-Coronado D, Martin A, Quack G. Studies with etofibrate in the rat. Part 1: Effects on glycerol, free fatty acid and triacylglycerol metabolism.  Biochim Biophys Acta. 1988;  963 42-52
  PubMedGoogle Scholar
• 34 Hollander P A, Elbein S C, Hirsch I B, Kelley D, McGill J, Taylor T, Weiss S R, Crockett S E, Kaplan R A, Comstock J, Lucas C P, Lodewick P A, Canovatchel W, Chung J, Hauptmann J. Role of orlistat in the treatment of obese patients with type 2 diabetes.  Diabetes Care. 1998;  21 1288-1294
  CrossrefPubMedGoogle Scholar
• 35 Howard B V, Robbins D C, Sievers M L, Lee E T, Rhoades D, Devereux R B, Cowan L D, Gray R S, Welty T H, Go O T, Howard W J. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL.  Arterioscler Thromb Vasc Biol. 2000;  20 830-835
  PubMedGoogle Scholar
• 36 Jastrzebska M, Zorbus-Lisiecka B, Pieczul-Mroz J, Chelstowski K, Kopciewicz M. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.  Int J Clin Pharmacol Res. 1999;  19 19-25
  PubMedGoogle Scholar
• 37 Julius U. Influence of free fatty acids on lipoprotein synthesis and diabetic dyslipidemia.  Exp Clin Endocrinol Diabetes. 2003;  (in press)
  PubMedGoogle Scholar
• 38 Kado S, Murakami T, Aoki A, Nagase T, Katsura Y, Noritake M, Matsuoka T, Nagata N. Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus.  Diab Res Clin Pract. 1998;  41 49-55
  CrossrefPubMedGoogle Scholar
• 39 Kawamura T, Egusa G, Fujikawa R, Watanabe T, Oda K, Kataoka S, Takayama S, Kubo K, Yamamoto S, Noma K, Orita R, Yamakido M. Effect of acarbose on glycemic control and lipid metabolism in patients with non-insulin-dependent diabetes mellitus.  Curr Ther Res. 1998;  59 97-105
  CrossrefPubMedGoogle Scholar
• 40 Kennedy L, Walshe K, Hadden D R, Weaver J A, Buchanan K D. The effect of intensive dietary therapy on serum high density lipoprotein cholesterol in patients with type 2 (non-insulin-dependent) diabetes mellitus: a prospective study.  Diabetologia. 1982;  23 24-27
  PubMedGoogle Scholar
• 41 Khan M A, St. Peter J V, Xue J L. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.  Diabetes Care. 2002;  25 708-711
  PubMedGoogle Scholar
• 42 Koskinen P, Manttari M, Manninen V, Huttunen J K, Heinonen O P, Frick M H. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.  Diabetes Care. 1992;  15 820-825
  CrossrefPubMedGoogle Scholar
• 43 Kreisberg R A. Diabetic dyslipidemia.  Am J Cardiol. 1998;  82 67U-73U
  CrossrefPubMedGoogle Scholar
• 44 Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais G R, Lupien P J, Depres J P. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study.  Circulation. 1997;  95 69-75
  PubMedGoogle Scholar
• 45 Lean M E, Powrie J K, Anderson A S, Gathwaite P H. Obesity, weight loss and prognosis in type 2 diabetes.  Diab Med. 1990;  7 228-233
  CrossrefPubMedGoogle Scholar
• 46 Leitersdorf E, Muratti E N, Eliav O, Meiner V, Eisenberg S, Dann E J, Sehayek E, Peters T K, Stein Y. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.  Am J Med. 1994;  96 401-407
  CrossrefPubMedGoogle Scholar
• 47 Mikhailidis D P, Papadakis J A, Ganotakis E S. Smoking, diabetes and hyperlipidemia.  J R Soc Health. 1998;  118 91-93
  CrossrefPubMedGoogle Scholar
• 48 Pereira M A, Jacobs D R, van Horn L, Slattery M L, Kartashov A I, Ludwig D S. Dairy consumption, obesity, and the insulin resistance syndrome in young adults.  JAMA. 2002;  287 2081-2089
  CrossrefPubMedGoogle Scholar
• 49 Pyörälä K, Pedersen T R, Kjekshus J, Faergeman O, Olsson A G, Thogeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4 S).  Diabetes Care. 1997;  20 614-620
  CrossrefPubMedGoogle Scholar
• 50 Rabkin S W, Boyko E, Streja D A. Changes in high density lipoprotein cholesterol after initiation of insulin therapy in noninsulin dependent diabetes mellitus: relationship to changes in body weight.  Am J Med Sci. 1983;  285 14-20
  PubMedGoogle Scholar
• 51 Reitsma J B, Castro-Cabezas M, de Bruin T WA, Erkelens D W. Relationship between improved postprandial lipemia and LDL metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor.  Metabolism. 1994;  43 293-298
  CrossrefPubMedGoogle Scholar
• 52 Rubins H B, Robins S J, Collins D, Fye C L, Anderson J W, Elam M B, Faas F H, Linares E, Schaefer E J, Schectman G, Wilt T J, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol,.  N Engl J Med. 1999;  341 410-418
  CrossrefPubMedGoogle Scholar
• 53 Sacks F M, Tonkin A M, Shepherd J, Braunwald E, Cobbe S, Hawkins M, Keech A, Packard C, Simes J, Byington R, Furberg C D. for the Prospective Pravastatin Pooling Project Investigators Group . Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project.  Circulation. 2000;  102 1893-1900
  PubMedGoogle Scholar
• 54 Schrezenmeir J, Keppler I, Fenselau S, Weber P, Biesalski H K, Probst R, Laue Ch, Zuchhold H D, Prellwitz W, Beyer J. The phenomenon of a high triglyceride response to an oral lipid load in healthy subjects and its link to the metabolic syndrome.  Ann NY Acad Sci. 1993;  683 302-314
  PubMedGoogle Scholar
• 55 Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J C. Mechanism of action of fibrates on lipid and lipoprotein metabolism.  Circulation. 1998;  98 2088-2093
  CrossrefPubMedGoogle Scholar
• 56 Steiner G. Treating lipid abnormalities in patients with type 2 diabetes mellitus.  Am J Cardiol. 2001;  88 (Suppl) 37N-40N
  PubMedGoogle Scholar
• 57 Steinmetz A, Fenselau S, Schrezenmeir J. Treatment of dyslipoproteinemia in the metabolic syndrome.  Exp Clin Endocrinol Diabetes. 2001;  109 S548-S559
  PubMedGoogle Scholar
• 58 Stern M P, Haffner S M. Dyslipidemia in type II diabetes. Implications for therapeutic intervention.  Diabetes Care. 1991;  14 1144-1159
  CrossrefPubMedGoogle Scholar
• 59 Stratton I M, Adler A I, Neil H A, Matthews D R, Manley S E, Cull C A, Hadden D, Turner R C, Holman R R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.  BMJ. 2000;  321 405-412
  CrossrefPubMedGoogle Scholar
• 60 Tan C E, Chew L S, Tai E S, Chio L F, Lim H S, Loh L M, Shepherd J. Benefits of micronised fenofibrate in type 2 diabetes mellitus subjects with good glycemic control.  Atherosclerosis. 2001;  154 469-474
  CrossrefPubMedGoogle Scholar
• 61 Taskinen M R. Triglyceride is the major atherogenic lipid in NIDDM.  Diabetes Metab Rev. 1997;  13 93-98
  CrossrefPubMedGoogle Scholar
• 62 Turner R C, Millns H, Neil H AW, Stratton I M, Manley S E, Matthews D R, Holman R R. for the United Kingdom Prospective Diabetes Study Group . Risk factors for coronary heart disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23).  BMJ. 1998;  316 823-828
  PubMedGoogle Scholar
• 63 United Kingdom Prospective Diabetes Study Group ( UKPDS). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).  Lancet. 1998 a;  352 854-865
  CrossrefPubMedGoogle Scholar
• 64 United Kingdom Prospetive Diabetes Study Group . United Kingdom Prospective Diabetes Study 24: A 6-year, randomised, controlled trial comparing sulphonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy.  Ann Intern Med. 1998 b;  128 165-175
  PubMedGoogle Scholar
• 65 Weber P, Schrezenmeir J, Fenselau S, Ausieker S, Probst R, Zuchhold H D, Prellwitz W, Beyer J. Prolonged postprandial increment in triglycerides and decreased postprandial response of VLDL in type 2 diabetics following an oral lipid load.  Ann NY Acad Sci. 1993;  683 315-322
  PubMedGoogle Scholar

M. D. Armin Steinmetz

St. Nikolaus-Stiftshospital GmbH Andernach
Teaching Hospital, University of Bonn

Hindenburgwall 1

56626 Andernach

Germany

Phone: + 4926324045497

Fax: + 49 2 63 24 04 56 40

Email: armin.steinmetz@stiftshospital-andernach.de